MIAT and atrial fibrillation: Overall, our study indicates that serum‐derived EVs can potentially carry MIAT, which binds to miR‐485‐5p and weakens its suppressive role on the target CXCL10, thus promoting the atrial remodeling and the consequent AF (Figure 9).